Abstract:Aim: Chronic iron overload resulting from frequent transfusions, poor compliance to efficient chelation therapy and chronic liver disease is basically responsible for the most severe complications of thalassemia major (TM). Before conventional treatment, TM was entirely childhood disease with a very short survival. Today, survival improved to 40-50 years and becomes a prevalent disease of adulthood and in the near future it will be one of senility. Furthermore, clinical phenotype of TM is changing with age and appearance of severe complications from the heart and endocrine glands that require special health care from well-informed specialists. Objectives: The aims of our study were to: (1) Imprint the clinical profile of long-lived TM patients; (2) evaluate retrospectively the cumulative incidence of endocrine diseases; (3) identify potential risk factors; and (4) orient the physicians in the modified clinical phenotype and the relative patients' health needs. Design: A retrospective cross-sectional study followed from childhood to adulthood by the same physician in a tertiary thalassemia clinic. Participants: Forty-three long-lived TM patients (mean age: 50.3 ± 10.8 years; range: 45.8-59.5 years; 23 females) were studied. Patients and methods: An extensive medical history, with detailed clinical and laboratory data, endocrine complications, and current treatments, was obtained. Results: The data indicate that 88.4% of adult TM patients suffered from at least one endocrine complication. The majority of patients developed endocrine complications in the second decade of life when serum ferritin level was very high (12/23 TM female and 8/20 TM male patients, the serum ferritin levels at the diagnosis were above 5.000 ng/ml). Conclusions: These data underline that endocrine and bone complications in adult TM patients are highly prevalent and necessitate close monitoring, treatment, and follow-up. Physicians' strategies to optimize chelation therapy include identifying patients who are at risk for developing organ damage, developing chelation plans, promoting compliance, and educating patients. Several clinical aspects remain to be elucidated such as growth and impairment of glucose tolerance in relation to hepatitis C virus infection. Furthermore, affordable worldwide-established long-term treatment protocols for hypogonadism and osteoporosis are needed.

Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience

How I manage medical complications of β-thalassemia in adults

Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years

Survival and Complications in Thalassemia

Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

Established Approaches, Old Issues, New Non-Curative Therapies, and Perspectives on Healing

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia

Iron overload: the Achilles heel of β- thalassemia

[Health status and quality of life in β-thalassemia adults in Marseille, France]

‘Phenoconversion’ in adult patients with β‐thalassemia

Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major

[Current management of thalassemia intermedia]

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia

Bone disease in β thalassemia patients: past, present and future perspectives

Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres

Beta thalassemia: Looking to the future, addressing unmet needs and challenges

Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease

Changing patterns in the epidemiology of β‐thalassemia

Endocrine profile of β-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center